Days Inventory is also known as Days Sales of Inventory (DSI). ViroPharma,'s Average Total Inventories for the
three
months ended in Sep. 2013 was €70.7 Mil. ViroPharma,'s Cost of Goods Sold for the
three
months ended in Sep. 2013 was €20.6 Mil.
Hence, ViroPharma,'s Days Inventory for the
three
months ended in Sep. 2013 was 314.03.
The historical rank and industry rank for ViroPharma,'s Days Inventory or its related term are showing as below:
FRA:VPH's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 194.42 * Ranked among companies with meaningful Days Inventory only.
ViroPharma,'s Days Inventory
increased
from Sep. 2012 (205.49) to Sep. 2013 (314.03).
It might indicate that ViroPharma,'s sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
ViroPharma,'s Inventory Turnover for the
three
months ended in Sep. 2013 was 0.29.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ViroPharma,'s Inventory-to-Revenue for the
three
months ended in Sep. 2013 was 0.84.
ViroPharma, Days Inventory Historical Data
The historical data trend for ViroPharma,'s Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ViroPharma,'s Days Inventory
For the Biotechnology subindustry, ViroPharma,'s Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroPharma,'s Days Inventory Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ViroPharma,'s Days Inventory distribution charts can be found below:
* The bar in red indicates where ViroPharma,'s Days Inventory falls into.
ViroPharma, Days Inventory Calculation
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
ViroPharma,'s Days Inventory for the fiscal year that ended in Dec. 2012 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroPharma, (FRA:VPH) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
ViroPharma,'s Inventory Turnover for the
three
months ended in Sep. 2013 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ViroPharma,'s Inventory to Revenue for the
three
months ended in Sep. 2013 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
ViroPharma, Days Inventory Related Terms
Thank you for viewing the detailed overview of ViroPharma,'s Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. It is a biotechnology company which develops and commercializes products that address serious diseases, used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On 8 January 2010, the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is consists of programs such as C1 esterase inhibitor [human], maribavir for cytomegalovirus infection, VP20621: prevention of recurrent CDAD and VP20629: treatment of Friedreich's Ataxia. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:VPH has been successfully added to your 